- CA$10.36m
- CA$71.03m
- CA$53.91m
- 29
- 71
- 18
- 33
Annual balance sheet for Valeo Pharma, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2019 October 31st | 2020 October 31st | 2021 October 31st | 2022 October 31st | 2023 October 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.335 | 2.84 | 2.04 | 22.5 | 7.5 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.613 | 1.22 | 1.8 | 5.43 | 6.57 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 1.65 | 5.41 | 12.3 | 40.5 | 25.2 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.296 | 0.605 | 2.14 | 2.25 | 2.66 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 5.81 | 11 | 21 | 58.3 | 41.2 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.48 | 4.28 | 15.3 | 15.3 | 20.3 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 5.83 | 7.89 | 19 | 76.1 | 81.5 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -0.022 | 3.07 | 2.05 | -17.8 | -40.3 |
| Total Liabilities & Shareholders' Equity | 5.81 | 11 | 21 | 58.3 | 41.2 |
| Total Common Shares Outstanding |